Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage biotech company Repros Therapeutics (NASDAQ: RPRX) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Repros and see what CAPS investors are saying about the stock right now.

Repros facts

Headquarters (founded)

The Woodlands, Texas (1987)

Market Cap

$208.1 million

Industry

Pharmaceuticals

Trailing-12-Month EBITDA

($12.7 million)

Management

CEO Joseph Podolski (since 1992)
CFO Katherine Anderson (since 2011)

Trailing-12-Month Return on Equity

(69.9%)

Cash/Debt

$29.6 million / $0

Competitors

Abbott Labs
Auxilium Pharmaceuticals
Actavis

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 54% of the 131 members who have rated Repros believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star TerryHogan, succinctly summed up the Repros bear case for our community:

They're burning through cash like a former child-star on a [V]egas bender, and they're handing out shares like they're breath mints at a halitosis convention. They have no revenues to speak of (in fact they don't have any revenue at all). And while the latest announcement about their clinical trial isn't exactly a nail in the coffin, it could be a sign of greater malfeasance.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.